Infants experienced fewer adverse effects with initial vaccinations of acellular diphtheria tetanus pertussis vaccine (DTaP) than with U.S.-licensed whole-cell DTP vaccine, according to a study published in the March Pediatric Infectious Diseases Journal.

DTaP has been licensed for booster vaccines in infants ages 15 months to 24 months, and ages 4 years to 6 years, but has not been licensed for younger infants in the United States.

This content is only available via PDF.
You do not currently have access to this content.